23:44 , Jul 25, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2019

New Therapeutic Targets and Biomarkers: June 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in June. Therapeutic targets are defined as any protein, gene or other molecule...
18:49 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

Ketorolac and resolvins to prevent cancer recurrence

DISEASE CATEGORY: Cancer INDICATION: Cancer, lung cancer, lymphoma, melanoma, colorectal cancer The generic COX inhibitor ketorolac and/or the resolvins RvD2, RvD3 and RvD4 could help prevent cancer recurrence due to chemotherapy- or surgery-induced inflammation. In...
19:32 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Solid tumors Cell culture and mouse studies suggest RvD1, RvD2 and RvE1 could help treat solid tumors. In a mouse model of lung cancer and a xenograft model of pancreatic cancer, intraperitoneal injection of...
23:28 , Nov 30, 2017 |  BC Extra  |  Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

In an article published in the Journal of Experimental Medicine , researchers at Beth Israel Deaconess Medical Center and colleagues showed that resolvins, a class of lipids, can suppress the pro-cancer activity of tumor debris...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Patient sample and mouse studies suggest RvD1 could help treat atherosclerosis. In carotid artery tissue samples from patients undergoing endarterectomy, levels of RvD1 were lower in unstable atherosclerotic plaques than in stable plaques...
07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Guillain-Barré syndrome (GBS) Mouse studies suggest RvD1 could help treat the acute inflammatory demyelinating polyneuropathy (AIDP) subtype of GBS. In a mouse model of AIDP, intraperitoneal RvD1 decreased demyelination of sciatic nerves and disease...
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Resolvin E1 (RvE1)

Inflammation INDICATION: Inflammation Mouse studies suggest RvE1 could help treat dermal inflammation. In a mouse model of contact hypersensitivity to dinitrofluorobenzene, RvE1 decreased migration of cutaneous dendritic cells to draining lymph nodes, and decreased levels...
07:00 , May 31, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infections Resolvin D1 (RvD1); RvD5 A study in mice suggests RvD1 and RvD5 could be useful for treating bacterial infections. In a mouse...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Celtic Therapeutics Holdings L.P., Resolvyx deal

Celtic exercised an October 2010 option from Resolvyx to receive exclusive, worldwide rights to RX-10045 for all ophthalmic indications. Resolvyx will receive an upfront payment and is eligible for milestones. Celtic will fund all further...